Highlights
- Biological valves offer a significantly higher chance of an uncomplicated pregnancy with a live birth (79%) compared to mechanical valves (54%).
- Low-molecular-weight heparin (LMWH) regimens were associated with the highest frequency of thromboembolic and hemorrhagic complications.
- A prosthetic valve in the mitral position is a potent predictor for valve thrombosis, carrying an odds ratio of 3.3.
- Fetal death remains a critical concern, occurring in 20% of all pregnancies involving prosthetic heart valves.
Introduction: The Clinical Dilemma of Prosthetic Valves in Pregnancy
The management of pregnant women with prosthetic heart valves remains one of the most challenging frontiers in cardio-obstetrics. While heart valve replacement allows women of childbearing age to survive and contemplate pregnancy, the choice of valve type—mechanical versus biological—sets the stage for a complex interplay between maternal safety and fetal viability. Mechanical valves, though durable, necessitate life-long anticoagulation, which becomes notoriously difficult to manage during the hypercoagulable state of pregnancy. Conversely, biological valves avoid the need for intensive anticoagulation but carry the risk of rapid structural valve deterioration (SVD) in younger patients.
Study Design and Methodology
The Registry of Pregnancy and Cardiac disease (ROPAC) III, part of the European Society of Cardiology (ESC) EuroObservational Research Programme (EORP), provides a global, prospective look at this population. Between January 2018 and April 2023, the registry enrolled 613 pregnancies in women with prosthetic heart valves. The cohort was divided into two primary groups: 411 pregnancies in women with mechanical heart valves (MHV) and 202 pregnancies in women with biological heart valves (BHV). The researchers meticulously collected data on anticoagulation strategies (including dosage and monitoring), cardiovascular events, and perinatal outcomes. The primary endpoint was the rate of uncomplicated pregnancy resulting in a live birth.
Key Findings: Biological vs. Mechanical Valve Outcomes
The results of the ROPAC III registry underscore a significant disparity in outcomes based on valve type. Women with biological valves experienced an uncomplicated pregnancy with a live birth in 79% of cases. In sharp contrast, this figure dropped to just 54% for women with mechanical valves (P < .001). This 25% gap is largely attributed to the necessity of anticoagulation in the mechanical valve group and the subsequent risks of thrombosis and hemorrhage.
Thrombotic and Hemorrhagic Complications
Valve thrombosis occurred in 24 women (6% of the total MHV group). The study identified that thromboembolic and hemorrhagic complications were most prevalent when low-molecular-weight heparin (LMWH)-based regimens were utilized. While LMWH is often preferred in the first trimester to avoid the teratogenic effects of Vitamin K Antagonists (VKAs) like warfarin, its use is fraught with dosing challenges.
The Mitral Position Risk
The anatomical position of the valve played a crucial role in risk stratification. A prosthetic valve in the mitral position was identified as a strong predictor for valve thrombosis, with an odds ratio of 3.3 (95% CI 1.9-8.0). This finding suggests that women with mitral mechanical valves require even more vigilant monitoring and perhaps more aggressive anticoagulation strategies compared to those with aortic mechanical valves.
The LMWH Paradox: Thrombosis and Monitoring
One of the most debated aspects of managing MHV in pregnancy is the use of LMWH and the necessity of monitoring anti-Xa levels. The ROPAC III data showed that thromboembolic events occurred in 10% of women who received anti-Xa monitoring, compared to 21% in those who did not. Although the P-value (0.060) did not reach the traditional threshold for statistical significance, the trend suggests a potential benefit for monitoring. However, the high rate of events even in the monitored group indicates that current LMWH protocols may be insufficient to fully mitigate risk in the highest-risk patients.
Fetal and Perinatal Outcomes
The burden on the fetus was substantial across the entire cohort. Fetal death occurred in 20% of all pregnancies. This high rate reflects both the direct effects of maternal complications (such as valve thrombosis or heart failure) and the potential embryopathy or placental hemorrhage associated with different anticoagulation regimens. The trade-off between maternal thrombotic protection and fetal safety remains the central conflict in MHV pregnancy management.
Clinical Implications and Expert Commentary
The ROPAC III registry provides essential evidence for pre-pregnancy counseling. For women requiring valve replacement who desire future pregnancy, the superior pregnancy outcomes of biological valves must be weighed against their limited long-term durability. For those already living with a mechanical valve, the registry highlights the precarious nature of LMWH therapy.
The Need for Standardized Protocols
The higher rate of complications with LMWH-based regimens suggests that transitioning between VKAs and LMWH, or using LMWH throughout pregnancy, requires expert multidisciplinary care. The borderline significance of anti-Xa monitoring suggests it should remain a standard of care, yet the high failure rate indicates a need for more frequent monitoring or more stringent target ranges.
Study Limitations
As a registry, the study is subject to selection bias and variations in local practice patterns across different global centers. Furthermore, while the registry tracks outcomes, it cannot definitively prove the superiority of one anticoagulation dosage over another without randomized controlled data, which remains ethically and practically difficult to obtain in this population.
Conclusion
The ESC EORP ROPAC III registry confirms that pregnancy in women with prosthetic heart valves—particularly mechanical valves—is a high-stakes clinical scenario. While biological valves offer a smoother course during pregnancy, mechanical valves demand a rigorous, individualized approach to anticoagulation. The identification of the mitral position as a specific risk factor and the high failure rate of LMWH regimens are critical takeaways for clinicians. Future research must focus on optimizing LMWH dosing schedules and exploring alternative anticoagulation strategies to bridge the gap in safety for these high-risk patients.
References
van der Zande JA, Ramlakhan KP, Sliwa K, Gnanaraj JP, Al Farhan H, Malhamé I, Otto CM, Vasallo Peraza R, Marelli A, Maggioni AP, Cornette JMJ, Johnson MR, Roos-Hesselink JW, Hall R, ROPAC investigators. Pregnancy with a prosthetic heart valve, thrombosis, and bleeding: the ESC EORP Registry of Pregnancy and Cardiac disease III. European heart journal. 2026-Mar-13;47(11):1318-1335. PMID: 40237423.
